大摩认为，京东健康线下投资与报销范围扩大为关键焦点领域，其持续扩张线下业务，第三季度开设50 多家药房门市，并计划第四季度新增约150家门市。值得注意，京东线上药房现已于7个城市(之前3个) 获得部分OTC(非处方)药个别帐户报销资格，包括北京、深圳、广州、东莞、渖阳、合肥及济南，视此 为未来数年更广泛覆盖的鼓舞性一步。 智通财经APP获悉，京东健康(06618)涨超3%，截至发稿，涨3.5%，报63.6港元，成交额2.41亿港元。 大摩发布研报指出，预期京东健康第三季度收入按年增约24%，主要是受到自有药品销售强劲(尤其是 慢性病领域)、营养产品超出预期支持，而医疗器械销售应符合预期。大摩续指，京东健康广告收入增 长速度应持续比产品销售更快，支持利润率进一步改善。凭借营运杠杆、严谨执行，以及线下投资可能 低于先前预期(比之前预期少1亿元人民币)，看到当前对2025财年收入预测增长20%、调整后营业利润35 亿元人民币及调整后净利润53亿元人民币，存在上行空间。 ...

Core Insights - The "Mind Art Exhibition" held from October 6 to October 10 coincides with World Mental Health Day, attracting over ten thousand visitors who participated in a collaborative painting activity [3][4] - JD Health, in collaboration with Wuhan University People's Hospital and Wuhan Mental Health Center, unveiled a large-scale community artwork titled "Free Heart," symbolizing a joint effort to promote mental health awareness and services [3][4] - The initiative represents an innovative approach to mental health services, emphasizing accessibility and community involvement through art and professional support [3][4] Company Initiatives - JD Health has established a comprehensive mental health service platform, featuring over 6,000 specialized doctors and 2,000 certified psychological counselors, offering services such as online psychological screening, assessments, consultations, and follow-ups [4] - The company aims to deepen collaborations with medical institutions, focusing on building a "famous doctors and hospitals" knowledge-sharing network, expanding "art therapy" services, and creating innovative academic platforms [4] - JD Health is committed to being a strong advocate for mental health, striving to make mental health services more understandable, accessible, and affordable for the public [4]

Core Insights - JD Health hosted the "Second Conference on Integration and Innovation in the Field of Mental Health" in Wuhan, highlighting its commitment to mental health services [1] - The new insomnia treatment drug, Daridorexant, achieved sales of over 5,000 boxes within 20 days of its launch [1] - JD Pharmacy launched a "Sleep Care Center" that integrates professional consultation, medication guidance, and health education to provide personalized sleep health services [1] Product Approval and Market Expansion - Daridorexant has received approvals in Europe, Switzerland, the UK, the US, Canada, and Japan, with the Chinese National Medical Products Administration approving it for market entry on June 20, 2025 [1] - The drug is indicated for the treatment of adult insomnia and is not classified under the "Controlled Psychotropic Substances" list [1] Future Development Plans - JD Health plans to continue promoting the integration of mental health and sleep medicine, enhancing collaboration with medical institutions and experts [1] - The company aims to improve service models to provide better sleep service experiences for users [1]

Group 1 - The core viewpoint highlights a significant shift towards "health consumption" during the recent National Day and Mid-Autumn Festival holidays, indicating a growing public awareness of health and a transformation in consumer attitudes [1] - During the 8-day holiday, traditional health products such as bird's nest, Ejiao cake, and Western ginseng saw explosive sales growth, with a year-on-year increase of 205% [1] - Modern nutritional supplements like lysine, protein powder, and glucosamine also experienced strong sales, with year-on-year growth rates of 200%, 85%, and 76% respectively, reflecting consumers' preference for practical and caring health products [1] Group 2 - The health consumption trend continues with the upcoming 11.11 shopping festival, where consumers can participate in promotional activities while purchasing health-related products [2] - During the 11.11 event, the number of limited-time free draw opportunities will double, and the maximum cash back amount will triple, enhancing the consumer experience [2]

Group 1 - Beijing Yaojing JD Health Comprehensive Clinic Co., Ltd. has been established with a registered capital of 5 million yuan [1] - The business scope includes clinic services, remote health management services, and retail of clothing and accessories [1] - The company is wholly owned by Suqian JD Tianning Health Technology Co., Ltd. [1]

Core Insights - The annual incidence of lung cancer in China reaches 1.06 million, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases, and the EGFR gene mutation being the most common driver gene with a mutation rate of about 50% [1] - There is a pressing demand for innovative treatment options with better efficacy and lower side effects for the large patient population [1] Group 1 - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals to explore new product launches and academic exchanges, aiming to build a patient-centered healthcare service system [1] - JD Health will leverage its comprehensive pharmaceutical supply chain and nationwide distribution network to ensure that innovative specialty drugs, including Lico®, can safely and efficiently reach users across the country [1] Group 2 - On October 9, Johnson & Johnson's innovative targeted drug Lico® (lanzetini mesylate tablets) was launched online on JD Health, designed for first-line treatment of EGFR mutation-positive advanced NSCLC in combination with evinacumab [3] - Lico® offers significant survival benefits and safety advantages, providing a breakthrough treatment option for the large lung cancer patient population in China [3] - JD Health aims to enhance the accessibility of this innovative treatment solution, allowing more Chinese lung cancer patients to benefit from it as early as possible [3]

Core Insights - Johnson & Johnson's innovative targeted drug, Lico® (lanzetini mesylate tablets), has been launched online on JD Health, providing a breakthrough treatment option for a large population of lung cancer patients in China [1][2] - The drug is used in combination with evan monoclonal antibody for first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), offering significant overall survival benefits and safety advantages [1] - JD Health aims to enhance the accessibility of this innovative treatment through its "first station for new specialty drugs" capabilities, ensuring more lung cancer patients can benefit from it [1] Industry Context - According to the 2024 National Cancer Report, there are 1.06 million new lung cancer patients annually in China, with approximately 85% being non-small cell lung cancer [1] - The mutation rate of the EGFR gene, the most common driver gene in NSCLC, is about 50%, indicating a high demand for more effective and safer innovative treatment options [1] - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson's Innovative Pharmaceuticals to leverage JD Health's supply chain and service capabilities alongside Johnson & Johnson's innovative drug portfolio in oncology and other key disease areas [1]

Core Viewpoint - Johnson & Johnson's innovative targeted drug, Lico (Lanzetini Mesylate Tablets), has been launched online on JD Health, providing a breakthrough treatment option for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) [1] Group 1: Product Launch - Lico is positioned as a first-line treatment in combination with Avelumab for advanced NSCLC, offering significant overall survival benefits and safety advantages [1] - The online launch on JD Health aims to enhance accessibility for a large population of lung cancer patients in China [1] Group 2: Strategic Partnership - JD Health and Johnson & Johnson Innovation Pharmaceuticals signed a strategic cooperation agreement in August, leveraging JD Health's supply chain and service capabilities [1] - The partnership will explore new product launches and academic exchanges, focusing on building a patient-centered healthcare service system [1]

Core Insights - The "Heart Maze Art Exhibition" in Wuhan features a special event led by Peng Kaiping, a prominent figure in positive psychology, focusing on emotional regulation techniques [1][3] - The exhibition, running from October 6 to October 10, aims to transform abstract psychological theories into immersive experiences, guiding visitors through a journey of emotional awareness and self-integration [3][4] - Peng Kaiping's "Aroma Therapy" is highlighted as a core method in the exhibition, utilizing olfactory senses to facilitate quick emotional adjustments based on neuroscience principles [3] Group 1 - The exhibition is a collaboration between JD Health, Wuhan University People's Hospital, and Wuhan Mental Health Center, emphasizing the theme of discovering one's true self beneath emotional fog [3] - The "Regulation" experience area features Peng Kaiping's therapy, which bypasses complex cognitive processes to directly evoke emotional memories [3] - Discussions at the event addressed common issues like weak social connections, with an emphasis on integrating health management and psychological adjustment into daily life [4] Group 2 - Peng Kaiping clarified misconceptions about positive psychology, stressing the need for a deeper understanding of mental health as a daily maintenance requirement, similar to physical health [4] - The exhibition combines art and science to create a tangible space for psychological well-being, allowing visitors to find personalized paths to harmonize with their emotions [4]

公司名稱: 京东健康股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結存 ...